Pfizer has a pill it's developing called danuglipron, which is in early-stage trials but has demonstrated that it's ...

The disappointing data Pfizer announced on its obesity pill are opening up opportunities for biotechs developing their own oral weight-loss drugs. Drugmakers are increasingly focused on the ...

Eli Lilly CEO David Ricks told investors this week that the sale of cheaper, knockoff versions of the company’s blockbuster ...

Pfizer ( PFE) raised its full-year guidance by $1.5 billion and posted strong third quarter earnings Tuesday. The company now ...

AstraZeneca said its experimental weight loss pill was well tolerated by patients ... Companies such as Pfizer, Roche and Viking Therapeutics are also developing oral GLP-1 weight-loss drugs.

Doubling down on the bad news, Pfizer's journey into the weight loss drug market has fallen flat, as its twice-daily obesity-fighting pill danuglipron triggered nausea and other stomach issues in ...

Pfizer has yet to distinguish itself in the increasingly competitive race for weight-loss primacy, and is continuing to work on a weight-loss pill. Bourla said in the May interview that the ...

which does not cover drugs specifically for weight loss. The drugmaker responsible for bringing the controversial abortion pill to the U.S. is now pursuing a new use that could widen women’s ...

Paxlovid, its antiviral pill, brought in $2.7 billion in sales ... FTC sues drug middlemen for allegedly inflating insulin ...

Novo Nordisk and Eli Lilly are also working on developing their own next-gen weight loss drugs. Pfizer seems to be primarily focused on incretin pills. Weight loss medications that already on the ...

Meanwhile, its weight-loss pill, danuglipron, stumbled in early trials — raising questions of whether Pfizer will get any piece of the weight-loss market pie before robust competition builds up.